Cipla Limited, in its Board Meeting held on May 13, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board recommended a final dividend of INR 13 per equity share for the financial year 2025-26. For the quarter ended March 31, 2026, the company reported consolidated revenue of INR 6,541.20 Crores, a decline of 7.54% from the previous quarter’s INR 7,074.48 Crores and a 2.80% decrease from INR 6,729.69 Crores in the same quarter last year. Net profit for the current quarter stood at INR 542.51 Crores, reflecting a 19.54% decline from the previous quarter and a significant 55.32% drop compared to the corresponding quarter of the previous year.

Export to Sheets

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening its portfolio in India, South Africa, North America, and key regulated and emerging markets. Founded in 1935, the company has grown into a major drugmaker, recently marking its 90th year of operations in 2025. A prominent figure associated with the company is Yusuf Hamied, the non-executive chairman and a billionaire philanthropist known for providing low-cost generic drugs. In recent updates from 2025 and 2026, Cipla received US FDA approval for the first AB-rated generic of Ventolin® HFA and expanded its respiratory portfolio with Nintedanib Capsules. The company also announced a scheme of amalgamation with its wholly-owned subsidiary, Inzpera Healthsciences Limited, in early 2026 to streamline operations.